Date:			10/10/2021		
Your Name:			Yuki Kataoka		
Manuscript Title:			Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study		
Ma	nuscript Number (if I	known):	Click or tap here to enter text.		
content of your manuscript. "Rela affected by the content of the ma		ript. "Rela of the ma	re ask you to disclose all relationships/activities/interests listed below that are related to the lated" means any relation with for-profit or not-for-profit third parties whose interests may be anuscript. Disclosure represents a commitment to transparency and does not necessarily of about whether to list a relationship/activity/interest, it is preferable that you do so.		
epi	-	nsion, yo		example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
	tem #1 below, report me for disclosure is th			ithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the	□ N	one		
1	All support for the present manuscript (e.g.,		one University	English editing	
1	present manuscript (e.g., funding, provision	Kyoto Scient	University ific Research Works Peer Support	English editing article processing fee	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing	Kyoto Scient Group	University		
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG)	article processing fee providing free Ali-M3 analysis and data	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG)	article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None — — — — — — — — — — — — — — — — — — —
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	No.	one	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	No.	one	
13	Other financial or non-financial interests	⊠ No	one	
Plea	•		ollowing statement to indicate your agreeme	

Date:			10/14/2021		
Your Name:			Yuya Kimura		
Manuscript Title:			Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study		
Ma	nuscript Number (if k	known):	Click or tap here to enter text.		
content of your manuscript. "Rela affected by the content of the ma		ript. "Rela of the ma	re ask you to disclose all relationships/activities/interests listed below that are related to the lated" means any relation with for-profit or not-for-profit third parties whose interests may be anuscript. Disclosure represents a commitment to transparency and does not necessarily of about whether to list a relationship/activity/interest, it is preferable that you do so.		
epi	· · · · · · · · · · · · · · · · · · ·	nsion, yo		example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
	tem #1 below, report me for disclosure is th			rithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the	□ N	one		
1	All support for the present manuscript (e.g.,			English editing	
1	present manuscript (e.g., funding, provision	Kyoto Scient	University ific Research Works Peer Support	English editing article processing fee	
1	present manuscript (e.g.,	Kyoto Scient Group	University		
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG)	article processing fee providing free Ali-M3 analysis and data	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG)	article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None — — — — — — — — — — — — — — — — — — —
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	No.	one	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	No.	one	
13	Other financial or non-financial interests	⊠ No	one	
Plea	•		ollowing statement to indicate your agreeme	

Date:	10/9/2021
Your Name:	Tatsuyoshi Ikenoue
Manuscript Title:	Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work		
p	All support for the present manuscript (e.g.,	□ None	
	funding, provision	Kyoto University	English editing
	of study materials, medical	Scientific Research Works Peer Support Group (SRWS-PSG)	article processing fee
	writing, article processing	M3 Inc. and Clinical Porter	providing free Ali-M3 analysis and data storage
	charges, etc.)  No time limit for		
	this item.		
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not	⊠ None	
	indicated in item #1 above).		

			ons/Comments (e.g., if payments were ou or to your institution)	
3	Royalties or licenses	None     ■		
4	Consulting fees	None     ■		
5	Payment or honoraria for lectures, presentations,	None		
	speakers			
	bureaus, manuscript			
	writing or educational events			
6	Payment for expert testimony	⊠ None		
7	Support for attending meetings and/or travel	None		
	traver			
8	Patents planned, issued or pending	None		
	B			
9	Participation on a Data Safety Monitoring Board or	None     ■		
	Advisory Board			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None     ■	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None  The analysis of the CT by Ali-M3 was carried out by Nobori on behalf of M3.	M3 and Nobori did not know the patients' data including the result of RT-PCR.  Nobori is a medical cloud company.  https://nobori.ltd/service/nobori_cloud/
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		
$\boxtimes$	I certify that I have	answered every question and have not altered the wo	ording of any of the questions on this form.

Date	e:	10/14/2021			
You	r Name:	Yoshinori Matsuoka	Yoshinori Matsuoka		
Manuscript Title:		E	Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study		
Mar	nuscript Number (if k	nown): Click or tap here to enter text.			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma		ipt. "Related" means any relation with for-profit or of the manuscript. Disclosure represents a commitm	re ask you to disclose all relationships/activities/interests listed below that are related to the lated" means any relation with for-profit or not-for-profit third parties whose interests may be anuscript. Disclosure represents a commitment to transparency and does not necessarily of about whether to list a relationship/activity/interest, it is preferable that you do so.		
epic	demiology of hyperter	os/activities/interests should be defined broadly. Fo nsion, you should declare all relationships with man entioned in the manuscript.			
	em #1 below, report and for disclosure is the	all support for the work reported in this manuscript e past 36 months.	without time limit. For all other items, the time		
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were		
		relationship or indicate none (add rows as needed	made to you or to your institution)		
		Time frame: Since the initial planning			
1	All support for the present	•			
1	All support for the present manuscript (e.g.,	Time frame: Since the initial plannir	g of the work  English editing		
1	All support for the present manuscript (e.g., funding, provision	Time frame: Since the initial plannin  ☐ None  Kyoto University Scientific Research Works Peer Support Group	g of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	Time frame: Since the initial plannin  ☐ None  Kyoto University	English editing article processing fee providing free Ali-M3 analysis and data		
1	All support for the present manuscript (e.g., funding, provision of study materials,	Time frame: Since the initial plannin  ☐ None  Kyoto University Scientific Research Works Peer Support Group (SRWS-PSG)	English editing article processing fee		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for	Time frame: Since the initial plannin  ☐ None  Kyoto University Scientific Research Works Peer Support Group (SRWS-PSG)	English editing article processing fee providing free Ali-M3 analysis and data		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Time frame: Since the initial plannin  ☐ None  Kyoto University Scientific Research Works Peer Support Group (SRWS-PSG)  M3 Inc. and Clinical Porter	English editing article processing fee  providing free Ali-M3 analysis and data storage		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: Since the initial plannin  ☐ None  Kyoto University Scientific Research Works Peer Support Group (SRWS-PSG)  M3 Inc. and Clinical Porter  Time frame: past 36 mon	English editing article processing fee  providing free Ali-M3 analysis and data storage		
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for	Time frame: Since the initial plannin  ☐ None  Kyoto University Scientific Research Works Peer Support Group (SRWS-PSG)  M3 Inc. and Clinical Porter	English editing article processing fee  providing free Ali-M3 analysis and data storage		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not	Time frame: Since the initial plannin  ☐ None  Kyoto University Scientific Research Works Peer Support Group (SRWS-PSG)  M3 Inc. and Clinical Porter  Time frame: past 36 mon	English editing article processing fee  providing free Ali-M3 analysis and data storage		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item	Time frame: Since the initial plannin  ☐ None  Kyoto University Scientific Research Works Peer Support Group (SRWS-PSG)  M3 Inc. and Clinical Porter  Time frame: past 36 mon	English editing article processing fee  providing free Ali-M3 analysis and data storage		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not	Time frame: Since the initial plannin  ☐ None  Kyoto University Scientific Research Works Peer Support Group (SRWS-PSG)  M3 Inc. and Clinical Porter  Time frame: past 36 mon	English editing article processing fee  providing free Ali-M3 analysis and data storage		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None — — — — — — — — — — — — — — — — — — —
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea 🖂		e following statement to indicate your agreeme ered every question and have not altered the wo	

Dat	e:		10/16/2021		
Υοι	ır Name:		Junichi Matsumoto		
			Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study		
Ma	nuscript Number (if k	nown):	Click or tap here to enter text.		
cor affe	tent of your manuscriected by the content o	ipt. "Rela of the ma			
epi	· ·	nsion, yo	es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.		
	tem #1 below, report a me for disclosure is the			rithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present	□ No	one		
1	present manuscript (e.g.,	Kyoto	University	English editing	
1	present	Kyoto Scient	University ific Research Works Peer Support		
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Kyoto Scient Group	University	English editing article processing fee providing free Ali-M3 analysis and data	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG)	English editing article processing fee	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG)	English editing article processing fee providing free Ali-M3 analysis and data	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG)	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	Kyoto Scient Group M3 Inc	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from	Kyoto Scient Group M3 Inc	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	Kyoto Scient Group M3 Inc	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None     Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None  M3 Inc.	Lecture fees
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None     Non	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None     Non	

			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	No.	one	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	No.	one	
13	Other financial or non-financial interests	⊠ No	one	
Plea	•		ollowing statement to indicate your agreeme	

Dat	e:	_	10/9/2021		
You	r Name:	_	Junji Kumasawa		
Ma	nuscript Title:		Integrated Model for COVID-19 Dia AI, and Clinical Features: A Multice	gnosis Based on Computed Tomography nter Cohort Study	
Ma	nuscript Number (if k	nown): _	Click or tap here to enter text.		
content of your manuscript. "Rela affected by the content of the ma			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.		
epi		nsion, you		example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
	rem #1 below, report on the for disclosure is the			ithout time limit. For all other items, the time	
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
			3	or the Work	
1	All support for the present	□ No	ne		
1	present manuscript (e.g., funding, provision of study materials,	Kyoto U Scientif		English editing article processing fee	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing	Kyoto U Scientif Group (	ne  Jniversity fic Research Works Peer Support	English editing	
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Kyoto U Scientif Group (	Iniversity fic Research Works Peer Support (SRWS-PSG)	English editing article processing fee providing free Ali-M3 analysis and data	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Kyoto U Scientif Group (	Iniversity fic Research Works Peer Support (SRWS-PSG)	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	Kyoto U Scientif Group (	Iniversity fic Research Works Peer Support (SRWS-PSG) . and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from	Kyoto L Scientif Group ( M3 Inc.	Iniversity fic Research Works Peer Support (SRWS-PSG) . and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	Kyoto L Scientif Group ( M3 Inc.	Jniversity fic Research Works Peer Support (SRWS-PSG) . and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto U Scientif Group ( M3 Inc.	Jniversity fic Research Works Peer Support (SRWS-PSG) . and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None — — — — — — — — — — — — — — — — — — —
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea 🖂		e following statement to indicate your agreeme ered every question and have not altered the wo	

Your Name:  Manuscript Title:			10/11/2021		
			Kentaro Tochitani		
			Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study		
Ma	nuscript Number (if k	nown):	Click or tap here to enter text.		
cor aff	tent of your manuscriected by the content of	ipt. "Rela of the ma	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be inuscript. Disclosure represents a commitment to transparency and does not necessarily it about whether to list a relationship/activity/interest, it is preferable that you do so.		
epi		nsion, yo	ies/interests should be defined broadly. For example, if your manuscript pertains to the ou should declare all relationships with manufacturers of antihypertensive medication, even if lin the manuscript.		
	tem #1 below, report me for disclosure is th		·	vithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
			Time traine. Since the initial planning	of the work	
1	All support for the	□ No	one	of the work	
1	present manuscript (e.g.,	Kyoto	University	English editing	
1	present manuscript (e.g., funding, provision	Kyoto Scient	University ific Research Works Peer Support		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing	Kyoto Scient Group	University	English editing	
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG)	English editing article processing fee providing free Ali-M3 analysis and data	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG)	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	Kyoto Scient Group M3 Inc	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	Kyoto Scient Group M3 Inc	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None — — — — — — — — — — — — — — — — — — —
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	No.	one	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	No.	one	
13	Other financial or non-financial interests	⊠ No	one	
Plea	•		ollowing statement to indicate your agreeme	

Dat	e:		10/10/2021		
Υοι	ır Name:		Hiraku Funakoshi		
Manuscript Title:			Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study		
Ma	nuscript Number (if k	(nown):	Click or tap here to enter text.		
content of your manuscript. "Rel affected by the content of the ma		ipt. "Rela of the ma	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be unuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so.		
epi	· ·	nsion, yo	ies/interests should be defined broadly. For example, if your manuscript pertains to the ou should declare all relationships with manufacturers of antihypertensive medication, even if lin the manuscript.		
	tem #1 below, report me for disclosure is th			ithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the	□ N•	one		
	present				
	present manuscript (e.g.,	Kyoto	University	English editing	
	manuscript (e.g., funding, provision	Scient	University ific Research Works Peer Support	English editing article processing fee	
	manuscript (e.g.,	Scient Group	University		
	manuscript (e.g., funding, provision of study materials, medical writing,	Scient Group	University ific Research Works Peer Support (SRWS-PSG)	article processing fee providing free Ali-M3 analysis and data	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Scient Group	University ific Research Works Peer Support (SRWS-PSG)	article processing fee providing free Ali-M3 analysis and data storage	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from	Scient Group	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from	Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	article processing fee providing free Ali-M3 analysis and data storage	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None — — — — — — — — — — — — — — — — — — —
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	No.	one	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	No.	one	
13	Other financial or non-financial interests	⊠ No	one	
Plea	•		ollowing statement to indicate your agreeme	

Date	e:		10/14/2021	
You	r Name:		Tomohiro Hosoda	
Mar	nuscript Title:		Integrated Model for COVID-19 Dia AI, and Clinical Features: A Multice	gnosis Based on Computed Tomography nter Cohort Study
Mar	nuscript Number (if	known):	Click or tap here to enter text.	
con affe	tent of your manusc cted by the content	ript. "Rela of the ma		
epic		ension, yo		example, if your manuscript pertains to the acturers of antihypertensive medication, even if
	em #1 below, report ne for disclosure is th		· · · · · · · · · · · · · · · · · · ·	ithout time limit. For all other items, the time
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present	□ No	one	
	manuscript (e.g.,		University	English editing
	funding, provision of study materials,		ific Research Works Peer Support (SRWS-PSG)	article processing fee
	medical writing, article processing		c. and Clinical Porter	providing free Ali-M3 analysis and data storage
	charges, etc.)  No time limit for			ciologo
	this item.			
			Time frame: past 36 month	s
2	Grants or contracts from	⊠ No	ne	
	any entity (if not			
	indicated in item #1 above).			
	·			
3	Royalties or	⊠ No	one	
	licenses			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None — — — — — — — — — — — — — — — — — — —
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	No.	one	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	No.	one	
13	Other financial or non-financial interests	⊠ No	one	
Plea	•		ollowing statement to indicate your agreeme	

Dat	e:		10/15/2021		
Your Name:			AIKO KUGIMIYA		
Manuscript Title:			Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study		
Maı	nuscript Number (if l	known):	Click or tap here to enter text.		
con affe	tent of your manusci ected by the content	ript. "Rela of the ma	re ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be anuscript. Disclosure represents a commitment to transparency and does not necessarily of about whether to list a relationship/activity/interest, it is preferable that you do so.		
epic		ension, yo	ies/interests should be defined broadly. For example, if your manuscript pertains to the bu should declare all relationships with manufacturers of antihypertensive medication, even if I in the manuscript.		
	em #1 below, report ne for disclosure is th		· · · · · · · · · · · · · · · · · · ·	rithout time limit. For all other items, the time	
			ll entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present	□ N	one		
	manuscript (e.g.,	Kyoto	University	English editing	
	funding, provision of study materials,		tific Research Works Peer Support (SRWS-PSG)	article processing fee	
	medical writing, article processing		c. and Clinical Porter	providing free Ali-M3 analysis and data storage	
	charges, etc.)  No time limit for			otorage	
	this item.				
			Time frame: past 36 month	s	
2	Grants or contracts from	⊠ No	ne		
	any entity (if not				
	indicated in item #1 above).				
3	Royalties or licenses	⊠ N	one		
	HCCH3C3				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None — — — — — — — — — — — — — — — — — — —
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea 🖂		e following statement to indicate your agreeme ered every question and have not altered the wo	

Date	e:		10/13/2021		
You	r Name:		Michinori Shirano		
Mar	nuscript Title:		Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study		
Mar	nuscript Number (if I	known):	Click or tap here to enter text.		
cont affe indi	tent of your manuscr cted by the content cate a bias. If you ar	ript. "Rela of the ma e in doubt		/interest, it is preferable that you do so.	
epid	-	ension, you	u should declare all relationships with manuf	acturers of antihypertensive medication, even if	
	em #1 below, report ne for disclosure is th			ithout time limit. For all other items, the time	
			ll entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ No	one		
			Time frame: past 36 month	s	
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ No	ne		
3	Royalties or licenses	No.	one		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None — — — — — — — — — — — — — — — — — — —
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	e following statement to indicate your agreeme	

Date:			10/16/2021		
Your Name:			Hamabe Fumiko		
			Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study		
Ma	nuscript Number (if k	nown):	Click or tap here to enter text.		
con affe	tent of your manuscriected by the content of	ipt. "Rela of the ma	re ask you to disclose all relationships/activities/interests listed below that are related to the lated" means any relation with for-profit or not-for-profit third parties whose interests may be anuscript. Disclosure represents a commitment to transparency and does not necessarily of about whether to list a relationship/activity/interest, it is preferable that you do so.		
epi		nsion, yo	ies/interests should be defined broadly. For example, if your manuscript pertains to the bu should declare all relationships with manufacturers of antihypertensive medication, even if I in the manuscript.		
	tem #1 below, report me for disclosure is th		·	vithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
			e ae. eee eeeu	of the work	
1	All support for the	□ No	one	of the work	
1	present manuscript (e.g.,	Kyoto	one University	English editing	
1	present manuscript (e.g., funding, provision	Kyoto Scient	University ific Research Works Peer Support		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing	Kyoto Scient Group	one University	English editing	
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Kyoto Scient Group	University iffic Research Works Peer Support (SRWS-PSG)	English editing article processing fee providing free Ali-M3 analysis and data	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Kyoto Scient Group	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from	Kyoto Scient Group	University  iffic Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Kyoto Scient Group M3 Inc	University  iffic Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	Kyoto Scient Group M3 Inc	University  iffic Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto Scient Group M3 Ind	University  iffic Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto Scient Group M3 Ind	University ific Research Works Peer Support (SRWS-PSG) c. and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None — — — — — — — — — — — — — — — — — — —
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None — — — — — — — — — — — — — — — — — — —
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None — — — — — — — — — — — — — — — — — — —

			all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:		-	10/10/2021		
Your Name:		_	Sachiyo Iwata		
Manuscript Title:		<u>-</u>	Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study		
Ma	nuscript Number (if k	known):	Click or tap here to enter text.		
content of your manuscript. "Rela affected by the content of the ma			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.		
epi		nsion, you	es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.		
In item #1 below, report all support frame for disclosure is the past 36				ithout time limit. For all other items, the time	
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the count	
			Time traine. Since the initial planning	of the work	
1	All support for the present	□ No	one	of the work	
1	present manuscript (e.g.,	Kyoto I	one University	English editing	
1	present	Kyoto I Scienti	one		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing	Kyoto I Scienti Group	University fic Research Works Peer Support	English editing	
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Kyoto I Scienti Group	University fic Research Works Peer Support (SRWS-PSG)	English editing article processing fee providing free Ali-M3 analysis and data	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Kyoto I Scienti Group	University fic Research Works Peer Support (SRWS-PSG)	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from	Kyoto I Scienti Group	University fic Research Works Peer Support (SRWS-PSG) . and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	Kyoto I Scienti Group M3 Inc	University fic Research Works Peer Support (SRWS-PSG) . and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not	Kyoto I Scienti Group M3 Inc	University fic Research Works Peer Support (SRWS-PSG) . and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto U Scienti Group M3 Inc	University fic Research Works Peer Support (SRWS-PSG) . and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Kyoto U Scienti Group M3 Inc	University fic Research Works Peer Support (SRWS-PSG) . and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or	Kyoto U Scienti Group M3 Inc	University fic Research Works Peer Support (SRWS-PSG) . and Clinical Porter  Time frame: past 36 month	English editing article processing fee providing free Ali-M3 analysis and data storage	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	10/16/2021
Your Name:	Shingo Fukuma
Manuscript Title:	Integrated Model for COVID-19 Diagnosis Based on Computed Tomography AI, and Clinical Features: A Multicenter Cohort Study
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were	
		relationship or indicate none (add rows as needed)	made to you or to your institution)	
		Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Kyoto University Scientific Research Works Peer Support Group (SRWS-PSG) M3 Inc. and Clinical Porter	English editing article processing fee providing free Ali-M3 analysis and data storage	
		Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None     ■		
3	Royalties or licenses	None None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:  I certify that I have answered every question and have not altered the wording of any of the questions on this form.			